




Curriculum Vitae

* CV must be written in English

Personal Information	
Title (i.e. Pf., Dr., etc.)	Prof
Name (First Name/ Middle Name /Last Name)	Taku Kobayashi
Degree (i.e. MD, MSc, PhD, etc.)	MD, PhD
Country	JAPAN
Affiliation	Kitasato University Kitasato Institute Hospital
E-mail	drkobataku@gmail.com
	
Educational Background	
1992-1998 Nagoya University School of Medicine, Nagoya, Japan (M.D.)	
2004-2008 Nagoya University Graduate School of Medicine, Nagoya, Japan (Ph.D.)	
Professional Career	
1998-2000 Residency in Medicine, Toyohashi Municipal Hospital, Aichi, Japan	
2000-2002 Residency in Internal Medicine, Toyohashi Municipal Hospital, Aichi, Japan	
2002-2004 Clinical Fellowship in Internal Medicine, KKR Tokai Hospital, Nagoya	
2004-2008 Researcher in Gastroenterology, Keio University, Tokyo, Japan	
2008-2009 Instructor, Department of Gastroenterology, Keio University, Tokyo, Japan	
2009-2012 Postdoctoral Research Associate, University of North Carolina at Chapel Hill, NC, USA	
2012-2013 Chief Physician, Department of Gastroenterology, Kitasato University Kitasato Institute Hospital	
2013-2022 Vice Director, Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital	
2014- 2022 Associate Professor/Vice Director, Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital	
2022-present Director, Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital	
2022-present Associate Professor, Department of Gastroenterology, Kitasato University School of Medicine	
2024-present Assistant Director of Kitasato University Kitasato Institute Hospital	
Research Field	
Inflammatory bowel disease	
Mucosal immunology	
Main Scientific Publications	
1. D'Haens G, Dubinsky M, Kobayashi T, M Irving P, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lisssoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, E Sands B, LUCENT Study Group Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>N Engl J Med.</i> 2023 Jun 29; 388(26):2444-2455.	
2. Allez M, Sands B, Feagan B, D'Haens G, De Hertogh G, Randall C, Zou B, Johanns J, O'Brien C, Curran M, Rebeck R, Wang ML, Sabins N, Baker T, Kobayashi T. A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients With Moderately to Severely Active Crohn's Disease. <i>J Crohns Colitis.</i> 2023 Aug 21; 17(8):1235-1251.	
3. Kobayashi T and Hibi T. Improving IBD outcomes in the era of many treatment options. <i>Nat Rev Gastroenterol Hepatol.</i> 2022 Mar; 20(3):195.	
4. Sagami S, Kobayashi T (Corresponding author), Aihara K, Umeda M, Odajima K, Morikubo H, Asonuma K, Miyatani Y, Fukuda T, Matsubayashi M, Kiyohara H, Nakano M, Hibi T. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. <i>Aliment Pharmacol Ther</i> 2022 May; 55(10):1320-	



1329.

5. Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Peyrin-Biroulet L, Colombel JF, Kaplan GG, Chen M. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials. *Gastroenterology* 2022 Feb; 162(2):482-494.

6. Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T, on behalf of the HAYABUSA Study Group. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. *The Lancet Gastroenterology & Hepatology* 2021 Jun; 6(6):429-437.

7. Kobayashi T [corresponding author shared], Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein C N, Danese S, Peyrin-Biroulet L, and Hibi T. Ulcerative colitis. *Nature Rev Dis Primers*. 2020 Sep 10; 6(1):74..

8. Kobayashi T [corresponding author], Uda A, Udagawa E, Hibi T. Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. *J Crohns Colitis* 2020 Jun 19; 14(5):617-623.

9. Matsuoka K, Kobayashi T* [first authorship shared], Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi K, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. *J Gastroenterol*. 2018 Mar;53(3):305-353.

10. Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R, Kitazume MT, Nakazawa A, Sugita A, Koganei K, Isobe K, Hibi T. IL-23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. *Gut*. 2008;57(12):1682-89.